These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on August 22, 2013.
Represents actual sale price.
Includes an aggregate of 12,655 shares of common stock issuable pursuant to previously reported restricted stock unit awards that have not vested.
The option became exercisable as to 25% of the shares on December 2, 2005, and becomes exercisable as to 1/48th of the shares each full month thereafter.
The above information was disclosed in a filing to the SEC. To see this filing in its entirety, click here. Genomic Health next reports earnings on April 28, 2014.
To receive a free e-mail notification whenever Genomic Health makes a similar move, sign up!